Nasdaq
$0.4354▼ 0.87%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $117.4MShares out 2.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 10.7After-hours26.10.08 05:064Ownership#●●●
Humacyte, Inc.
Insider D. Scott Coward of Humacyte, Inc. reported a change in beneficial ownership of company securities as of October 6, 2026. This filing is a Form 4 statement detailing the insider's shareholding activity.…more
$0.4354-0.87%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7After-hours26.10.08 05:054Ownership
Humacyte, Inc.
Humacyte, Inc. insider Paul Brian Kuznik filed a Form 4 on October 6, 2026, reporting a change in beneficial ownership of securities. This filing serves as an official disclosure of the insider's equity transaction to the SEC.…more
$0.4354-0.87%vs prev closeView filingShare - 9.28After-hours26.09.29 05:073Ownership
Humacyte, Inc.
Paul Kuznik, a shareholder of Humacyte, Inc., has filed a Power of Attorney appointing Dale A. Sander as his attorney-in-fact. This authorization enables the designated attorney to execute and file required SEC documents, including Forms 3, 4, 5, and Schedules 13D and 13G, on behalf of the shareholder regarding his holdings in the company.…more
$0.4354-0.87%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 21:03#●●●#●●●
Humacyte Reports Positive Interim Phase 3 Results for ATEV in Hemodialysis Patients…more
Humacyte announced positive interim results from its Phase 3 V012 trial, showing that ATEV significantly outperformed standard arteriovenous fistula in female hemodialysis patients. The treatment met its primary endpoint by reducing catheter-free time and achieving functional access faster than the current standard of care.…more
$0.4354-0.87%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 2d agoPre-market26.10.23 21:00
●●●●●●●● ●●●●● ●●●●●●
Humacyte's ATEV demonstrated a significant reduction in catheter-free time compared to standard fistulas in a Phase 3 trial for female hemodialysis patients. The company plans to submit a supplemental BLA to the FDA this quarter based on these positive interim results.…more
$0.4354-0.87%vs prev close - 10.15Pre-market26.10.15 22:18
●●●●●●●● ●●●●● ●●●●●●
Humacyte announced that the number of hospitals ordering its Symvess product grew by 44% in the third quarter, reaching 49 facilities. While the company highlights accelerating commercial adoption and surgeon interest, specific financial results were not disclosed.…more
$0.4354-0.87%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report